MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Advanced Cell Technology, Inc. (ACTC) Continues Clinical Trials; Receives $35 Million Funding Commitment 1 comment
    Oct 23, 2012 2:43 PM | about stocks: D

    Advanced Cell Technology, a leader in the field of regenerative medicine, recently announced treatment of the fourth patient, the first in the second patient cohort, in its European clinical trial for Stargardt's Macular Dystrophy (SMD). The patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with 50,000 cells in the three patients comprising the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully.

    "Our progress continues in our European clinical trial and both our trials in the U.S., as seen most recently with last week's announcement of treatment of the second patient in the second patient cohort of our U.S. trial for SMD," said Gary Rabin, chairman and CEO of ACTC. "As I mentioned last week, we have mapped out the series of patients to complete the second cohort of both our trials for SMD, as well as for our trial for dry age-related macular degeneration (dry AMD), pending DSMB review, and we anticipate generating patient data at a faster pace."

    ACTC, known as a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide, is excited about the trial's progress. Having only been initiated in January, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint.

    ACTC also recently announced that it had entered into a $35 million common stock purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor. Proceeds from this transaction will be used to fund the company's clinical activities, including its three ongoing Phase I/II clinical trials for forms of macular degeneration, for development of its other clinical activities, and for general corporate purposes.

    "We are most pleased about this financing agreement, as it has a number of notable benefits for the company," commented Gary Rabin, chairman and CEO of ACTC. "Lincoln Park Capital is an excellent partner for us with a great track record and a long-term commitment to the life sciences field. This transaction offers the Company a very cost efficient and readily available form of financing. The $35 million available under the agreement equates to more than two years of funding for the Company, even assuming no other sources of capital. It was a priority for us to complete a new financing by year-end, as we never again want to be in a position to have to go looking for capital from a position of distress or weakness. This agreement strengthens our balance sheet allowing us to focus on advancing our clinical programs, pursuing strategic partnerships, and other long-term objectives."

    For more information on ACTC, visit www.advancedcell.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: D
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • Bunkerdude
    , contributor
    Comments (50) | Send Message
    Great article, tho more information on the deal will be forthcoming we all hope.
    Funding for this paragram shift in treatments for un-met needs is so much more important than many understand. However from strictly a stock holders position it is a positive as well not to worry about future funding for the world changing trials.


    Long ACTC and still very excited for the future of this important company.
    14 Nov 2012, 04:08 PM Reply Like
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.